Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target

Currently, the world suffers from a new coronavirus SARS-CoV-2 that causes COVID-19. Therefore, there is a need for the urgent development of novel drugs and vaccines for COVID-19. Since it can take years to develop new drugs against this disease, here we used a hybrid combined molecular modeling approach in virtual drug screening repurposing study to identify new compounds against this disease. One of the important SARS-CoV-2 targets namely type 2 transmembrane serine protease (TMPRSS2) was screened with NPC’s NIH small molecule library which includes approved drugs by FDA and compounds in clinical investigation. We used 6654 small molecules in molecular docking and top-50 docking scored compounds were initially used in short (10-ns) molecular dynamics (MD) simulations. Based on average MM/GBSA binding free energy results, long (100-ns) MD simulations were employed for the identified hits. Both binding energy results as well as crucial residues in ligand binding were also compared with a positive control TMPRSS2 inhibitor, Camostat mesylate. Based on these numerical calculations we proposed a compound (benzquercin) as strong TMPRSS2 inhibitor. If these results can be validated by in vitro and in vivo studies, benzquercin can be considered to be used as inhibitor of TMPRSS2 at the clinical studies.

PDF

___

Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D et al. (2020). Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19, Cell 181 (5): 1036-1045.
Cao Y, Li L, Feng Z, Wan S, Huang P et al. (2020). Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARSCoV-2) receptor ACE2 in different populations. Cell Discovery 6: 1-4.
Durdagi S, Aksoydan B, Erol I, Kantarcioglu I, Ergun Y et al. (2018) Integration of Multi-scale Molecular Modeling Approaches with Experiments for the in silico Guided Design and Discovery of Novel hERG-Neutral Antihypertensive Oxazalone and Imidazolone Derivatives and Analysis of Their Potential Restrictive Effects on Cell Proliferation. European Journal of Medicinal Chemistry 145: 273-290
Durdagi S, Aksoydan B, Dogan B, Sahin K, Shahraki A et al. (2020) Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. ChemRxiv. doi: 10.26434/chemrxiv.12032712.v2
Evans DJ, Holian BL (1985). The Nose–Hoover thermostat. Journal of Chemical Physics 83: 4069-4074. doi: 10.1063/1.449071
Hoffmann M, Kleine-Weber H, Krüger N, Herrler T, Erichsen S et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181 (2): 271-280.
Is YS, Durdagi S, Aksoydan B, Yurtsever M (2018). Proposing Novel MAO-B Hit Inhibitors Using Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of their Therapeutic Activity and Toxic Effects. ACS Chemical Neuroscience 9 (7): 1768-1782.
Martyna GJ, Tobias DJ, Klein ML (1994). Constant pressure molecular dynamics algorithms. The Journal of Chemical Physics 101 (5): 4177-4189.
McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C (2020). Candidate drugs against SARS-CoV-2 and COVID-19 [published online ahead of print, 2020 Apr 29]. Pharmacological Research 157: 104859. doi: 10.1016/j.phrs.2020.104859
Mousavizadeh L, Ghasemi S (2020). Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology, Immunology and Infection ISSN 1684-1182. doi: 10.1016/j.jmii.2020.03.022
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020). Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review [published online ahead of print, 2020 Apr 13]. doi: 10.1001/jama.2020.6019. DOI:10.1001/ jama.2020.6019
Shoichet BK, McGovern, SL, Wei B, Irwin JJ (2002). Lead discovery using molecular docking. Current Opinion in Chemical Biology 6: 439-446.
Tutumlu G, Dogan B, Avsar T, Orhan MD, Calis S (2020). Integrating Ligand and Target-Driven Based Virtual Screening Approaches with in vitro human Cell Line Models to Identify Novel Hit Compounds Against BCL-2. Frontiers in Chemistry. doi: 10.3389/fchem.2020.00167
Zhang R, Wang X, Ni L, Di Xiao, Baitao M (2020). COVID-19: Melatonin as a potential adjuvant treatment. Life Sciences, 250:117583. doi: 10.1016/j.lfs.2020.117583